CSU

Jasper Therapeutics Announces Preclinical Data Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

Retrieved on: 
Montag, Februar 5, 2024
Poster, Syndrome, AAAAI, CD117, Mouse, Annual general meeting, CSU, Therapy, Risk, Vaccine

REDWOOD CITY, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) in mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), as well as lower to intermediate risk myelodysplastic syndromes (LR-MDS) and novel stem cell transplant conditioning regimens, today announced two poster presentations and an oral presentation of preclinical briquilimab data at the AAAAI 2024 Annual Meeting, being held February 23-26 in Washington, D.C.

Key Points: 
  • REDWOOD CITY, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) in mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), as well as lower to intermediate risk myelodysplastic syndromes (LR-MDS) and novel stem cell transplant conditioning regimens, today announced two poster presentations and an oral presentation of preclinical briquilimab data at the AAAAI 2024 Annual Meeting, being held February 23-26 in Washington, D.C.
  • Details of the presentations are as follows:
    Abstract Title: Amelioration Of Mrgprb2-Mediated Anaphylactoid Drug Reactions With Briquilimab, An Anti-CD117 Antibody, Through Mast Cell Depletion In Mice Expressing Chimeric Human And Mouse CD117

Jasper Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Freitag, Februar 2, 2024
Option, Syndrome, CD117, Employment, CSU, Therapy, Risk

Each Option was granted pursuant to the Jasper Therapeutics, Inc.

Key Points: 
  • Each Option was granted pursuant to the Jasper Therapeutics, Inc.
  • Amended and Restated 2022 Inducement Equity Incentive Plan, as approved by the compensation committee of Jasper’s board of directors on March 14, 2022 and as amended and restated on June 2, 2023, and was granted as an inducement material to such employee’s employment with Jasper in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The exercise price of each Option is $11.78.
  • Each Option will vest over four years, with 25% of the total number of shares vesting on the one year anniversary of the date of commencement of such employee’s employment with Jasper and 1/48th of the total number of shares subject to each Option vesting monthly thereafter, subject in each case to such employee’s continued service to Jasper on each vesting date.

Federal Alliance for Safe Homes Names Mike Buresh 2024 National Weatherperson of the Year

Retrieved on: 
Freitag, Februar 2, 2024
Meteorologist, WNEP, ABC, Life, Meteorology, Fox Weather, Iowa State University, Federal Alliance (South Africa), Research, WJAX, FOX, Safety, Action News, FLASH, NWP, WVUE, Atmosphere, American Meteorological Society, Hurricane season, WFOX, JAX, Tornado, Weather, Flood, CSU, Colorado State University, National Hurricane Center, Education, Death, First Coast, Face, Jax, Forecasting

TALLAHASSEE, Fla., Feb. 2, 2024 /PRNewswire/ -- Today, the Federal Alliance for Safe Homes, Inc. (FLASH) named Mike Buresh, Chief Meteorologist, Action News JAX - WJAX, WFOX as the 2024 National Weatherperson of the Year (NWP). This annual accolade acknowledges weather professionals who exhibit exemplary leadership in advocating for disaster safety and resilience.

Key Points: 
  • TALLAHASSEE, Fla., Feb. 2, 2024 /PRNewswire/ -- Today, the Federal Alliance for Safe Homes , Inc. (FLASH) named Mike Buresh, Chief Meteorologist, Action News JAX - WJAX, WFOX as the 2024 National Weatherperson of the Year (NWP).
  • The 2024 winner describes himself as not just a weather expert but a "weatherholic" whose lifelong passion for meteorology began in his early years in rural Iowa.
  • His career highlights include providing accurate warnings and tracking information for weather events, including tornadoes, waterspouts, floods, and local tropical cyclones.
  • We congratulate Mike and all of our outstanding 2024 National Weatherperson of the Year finalists who serve the public with unwavering excellence every day, especially during hurricane season."

Cincinnati Financial Corporation Announces Executive Leadership Transition, Expands Board to 14, Appoints Two New Directors

Retrieved on: 
Freitag, Januar 26, 2024
Boston Consulting Group, Cincinnati Financial, CSU, Associate, Casualty, CINF, Insurance, Casualty Actuarial Society, Spray, Intelligence, American Academy, Society of Actuaries, Annual general meeting, Marketing, Data science, Growth, Management

"Steve is the ideal candidate to lead the company forward," commented Steve Johnston, chairman and chief executive officer.

Key Points: 
  • "Steve is the ideal candidate to lead the company forward," commented Steve Johnston, chairman and chief executive officer.
  • Additionally, Mr. Wu was appointed to the audit committee and Mr. Spray to the executive committee of the board, effective immediately.
  • Spray, age 57, serves as president of Cincinnati Financial Corporation and its U.S.-based subsidiaries.
  • Johnston noted, "Our shareholders benefit from our highly engaged board of directors who bring their wide range of experiences and skills.

Romulus Co-Presidents Scott Smith & Tom George Recognized in 2024's Swanepoel Power 200 List

Retrieved on: 
Mittwoch, Januar 17, 2024
Constellation, Smith, Organization, Swanepoel, TSX, CSU, Acquisition, Human, Growth, Management

BELLEVUE, Wash., Jan. 17, 2024 /PRNewswire-PRWeb/ -- Romulus, a portfolio of vertical market software companies within Constellation Software Inc. (TSX: CSU), is proud to announce that its co-presidents have been included in the tenth annual Swanepoel Power 200 (SP 200) list of the residential real estate industry's most influential executives.

Key Points: 
  • Scott Smith, a veteran in the real estate industry since 2002, has been a key figure at Constellation Software Inc. since its acquisition of Market Leader in 2015.
  • Tom George has spent over 25 years acquiring and managing technology companies, with the last 20 years in the real estate, finance, and home builder verticals.
  • Today he spearheads acquisition efforts and co-manages the portfolio of Romulus companies, which currently serves over 500,000 customers with 3,000 employees.
  • "I know I speak for Tom and all Romulus business units when I say, being recognized in the Swanepoel Power 200 is truly an honor," Smith said.

Allakos Announces a Restructuring to Focus on Development of AK006

Retrieved on: 
Dienstag, Januar 16, 2024
Allergy, Patient, CSU, Research, SAN, PD, Investment, SAD, Safety, Antibody, Workforce, Pharmacokinetics, Pharmaceutical industry

AK006 is being tested in a comprehensive Phase 1 clinical program, including:

Key Points: 
  • AK006 is being tested in a comprehensive Phase 1 clinical program, including:
    Management to host conference call and webcast today at 8:00 am E.T.
  • SAN CARLOS, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the Company) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today announced a restructuring to reduce costs and to focus on AK006 clinical development and additional preclinical programs.
  • The Company ended the fourth quarter of 2023 with approximately $171 million in cash, cash equivalents and investments (unaudited).
  • Year End 2024: Report topline data from the Phase 1 trial of IV AK006 in patients with CSU.

Colorado State University Global Announces Master of Business Administration in Product Management

Retrieved on: 
Dienstag, Januar 9, 2024
Student, GMAT, CSU, Graduate Record Examinations, Business administration, Curriculum, Graduate Management Admission Test, Workplace, MBA, Colorado State University–Global Campus, Ideation, Product management, Workforce, Marketing, Master of Business Administration, GRE, Management

Aurora, Colo., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Colorado State University Global (CSU Global) today announced its fully online Master of Business Administration (MBA) in Product Management program.

Key Points: 
  • Aurora, Colo., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Colorado State University Global (CSU Global) today announced its fully online Master of Business Administration (MBA) in Product Management program.
  • The cross-functional program integrates skills in product design, marketing, branding, supply chain, and finance, making graduates proficient in the entire product or service life cycle and competitive across diverse markets.
  • Tailored to meet the needs of busy professionals, the program can be completed for a maximum of $16,500 and in 20 months or less.
  • In addition, for a smooth enrollment process for this program, CSU Global does not require a Graduate Record Examinations General Test (GRE) or a Graduate Management Admission Test (GMAT).

Liaison Launches Expanded Transfer Planner to Help California State University Streamline Higher Education Paths for Community College Transfers

Retrieved on: 
Dienstag, Januar 9, 2024
Transfer, Student, CSU, Senior counsel, Educational technology, Partnership, International, University, GPA, Marketing, Education, California State University, Management

Developed as part of a joint initiative with the California State University system, this targeted solution increases access and student success among community college students seeking to advance their education.

Key Points: 
  • Developed as part of a joint initiative with the California State University system, this targeted solution increases access and student success among community college students seeking to advance their education.
  • More than 40% of the CSU's undergraduate students transfer from the state's large community college network.
  • Liaison's enhanced feature set allows students to:
    Enter college courses and monitor their progress toward transfer, including transfer units earned and transfer GPA.
  • Leveraging the expanded feature set of Liaison's Transfer Planner platform, the CSU is empowering community college students to navigate their academic paths with greater ease, seize opportunities for academic growth, and pursue their dreams of higher education.

Jasper Therapeutics Highlights Recent Accomplishments and Key Upcoming Milestones

Retrieved on: 
Freitag, Januar 5, 2024
Omalizumab, Subcutaneous, CD117, Risk, IND, EMA, FA, Chairperson, Cold urticaria, Therapy, MDS, Chronic, Fanconi anemia, ASH, Annual general meeting, European Medicines Agency, Syndrome, CSU, SVP, Patient, Acute myeloid leukemia, Safety, AML, CTA, Pharmaceutical industry

REDWOOD CITY, Calif., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) in mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), as well as lower to intermediate risk myelodysplastic syndromes (LR-MDS) and novel stem cell transplant conditioning regimens, today announced its recent accomplishments, including the authorization by the European Medicines Agency (EMA) of the Company’s Clinical Trial Applications (CTA) for its Phase 1b/2a trials of briquilimab in CIndU and CSU, and outlined its corporate priorities and anticipated milestones for 2024. Called SPOTLIGHT – “Study (Phase 1b/2a) Of subcuTaneous brIquilimab in patients diaGnosed with cHronic inducible urTicaria” – the CIndU study will evaluate single doses of subcutaneous briquilimab in adult patients with cold urticaria or symptomatic dermographism.

Key Points: 
  • “2023 was a strategically important year for Jasper,” said Ronald Martell, President and Chief Executive Officer of Jasper.
  • “We secured IND clearance and CTA authorization for the Phase 1b/2a BEACON study of briquilimab in CSU and successfully dosed the first patient.
  • Our achievements in 2023 set the stage for a transformational year ahead with multiple key clinical milestones on the horizon across multiple indications.
  • Strengthened the organization with key leadership appointments including Thomas Wiggans as Chairperson of the Board of Directors, Scott Brun, M.D.

Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs and 2024 Outlook at the 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Donnerstag, Januar 4, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, Virology, Conference, Heart, Partnership, RSV, FDA, Medication, Chronic obstructive pulmonary disease, Disease, Hepatitis, KIT, Viral load, ADME, Pharmacokinetics, Asthma, COVID-19, CSU, Webcast, Patient, Safety, Therapy, Fast Track, Pharmaceutical industry

Our foundational capabilities in virology and small molecule drug development transition well to immunology, an adjacent field where we can leverage our core strengths.

Key Points: 
  • Our foundational capabilities in virology and small molecule drug development transition well to immunology, an adjacent field where we can leverage our core strengths.
  • The company has developed novel, potent and selective oral inhibitors of KIT, which are now being optimized in preclinical development.
  • Enanta will present new preclinical data on its prototype KIT inhibitor at the J.P. Morgan Conference and is targeting the selection of a development candidate in 2024.
  • A replay of the webcast will be available following the presentation and will be archived for approximately 60 days.